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Background: REQUITE (validating pREdictive models and biomarkers of radiotherapy
toxicity to reduce side effects and improve QUalITy of lifE in cancer survivors) is an
international prospective cohort study. The purpose of this project was to analyse a
cohort of patients recruited into REQUITE using a deep learning algorithm to identify
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patient-specific features associated with the development of toxicity, and test the
approach by attempting to validate previously published genetic risk factors.
Methods: The study involved REQUITE prostate cancer patients treated with external
beam radiotherapy who had complete 2-year follow-up. We used five separate late
toxicity endpoints: ≥grade 1 late rectal bleeding, ≥grade 2 urinary frequency, ≥grade 1
haematuria, ≥ grade 2 nocturia, ≥ grade 1 decreased urinary stream. Forty-three single
nucleotide polymorphisms (SNPs) already reported in the literature to be associated with
the toxicity endpoints were included in the analysis. No SNP had been studied before
in the REQUITE cohort. Deep Sparse AutoEncoders (DSAE) were trained to recognize
features (SNPs) identifying patients with no toxicity and tested on a different independent
mixed population including patients without and with toxicity.
Results: One thousand, four hundred and one patients were included, and toxicity rates
were: rectal bleeding 11.7%, urinary frequency 4%, haematuria 5.5%, nocturia 7.8%,
decreased urinary stream 17.1%. Twenty-four of the 43 SNPs that were associated with
the toxicity endpoints were validated as identifying patients with toxicity. Twenty of the
24 SNPs were associated with the same toxicity endpoint as reported in the literature:
9 SNPs for urinary symptoms and 11 SNPs for overall toxicity. The other 4 SNPs were
associated with a different endpoint.
Conclusion: Deep learning algorithms can validate SNPs associated with toxicity
after radiotherapy for prostate cancer. The method should be studied further to identify
polygenic SNP risk signatures for radiotherapy toxicity. The signatures could then be
included in integrated normal tissue complication probability models and tested for their
ability to personalize radiotherapy treatment planning.
Keywords: prostate cancer, late toxicity, snps, deep learning, autoencoder, validation
INTRODUCTION
Radiotherapy represents themost effective non-surgical modality
for the potentially curative treatment of prostate cancer. Around
a half of survivors underwent radiotherapy as part of their
curative care (1), either as single curative treatment or as
adjuvant/salvage treatment after radical prostatectomy.
Despite the fact that prognosis is very good in terms of
patients’ survival rates, it is widely acknowledged that long-
term side-effects after radiotherapy can affect a patient’s quality-
of-life (2–4). A tool able to identify patients likely to develop
toxicity could be a crucial step toward personalized radiotherapy
with modification of the dose, fractionation, techniques and
supportive care. The ultimate goal is to reduce morbidity and
improve quality-of-life.
Radiation toxicity is a multifactorial problem, related not
only to the cumulative delivered dose, but also to an intrinsic
process within tissues responding to cellular injury. Individual
genetic background and biological expression pattern, premorbid
conditions, concomitant oncological therapies, as well as the
cellular microenvironment, could be important factors in the
development of side-effects, although their exact contributions
are unknown.
With increased interest in this field and relevant data
collection on this topic, predictive models have been developed
to identify patients likely to develop side effects during
radiotherapy (3).
The identification of genetic factors associated with
susceptibility to radiation toxicity represents an emerging
research area in oncology. A number of different
approaches have been explored (5–13), however, the
developed models and biomarkers have failed to progress
to routine clinical use due to the lack of thorough
independent validation.
REQUITE (validating pREdictive models and biomarkers
of radiotherapy toxicity to reduce side effects and improve
QUalITy of lifE in cancer survivors) was established with the
aim of validating models and biomarkers for the prediction
of adverse effects following radiotherapy (14–16). In order
to address previous limitations in pooling data, in using
common toxicity scoring systems and in collecting standardized
data, REQUITE carried out an international, multi-center,
prospective observational study. A centralized biobank was
also established to store blood samples and genome-wide
genotyping of single nucleotide polymorphisms (SNPs) was
carried out.
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The specific purpose of the present study was to attempt to
validate genetic risk factors for late toxicity (rectal bleeding and
late urinary symptoms) after prostate cancer radiotherapy in
the REQUITE population using a deep learning algorithm. This
technique aims to identify patient-specific features that define
patients with toxicity (“unhealthy”) as outliers with respect to the
population of irradiated patients without toxicity (“healthy”).
Deep learning has the potential to overcome the difficulties
in replication of results faced by the widespread single-SNP
association methods used by genome wide association studies
(GWAS). The statistical power of GWAS is limited by a
combination of the large number of hypotheses being tested
simultaneously and the inherently small effect size of the single
SNP (17).
Deep learning approaches, with their intrinsic hierarchical
structure (where each layer performs a combination of the
outcomes of the previous layers), seem particularly adapt at
mimicking complex dependencies within data. The method
addresses effectively the following issues: (i) unstable selections
of correlated variables and inconsistent selections of linearly
dependent genetic variables (18); (ii) strong imbalance between
positive and negative outcomes which is usually encountered in
studies of radiation toxicity.
MATERIALS AND METHODS
Population
REQUITE prostate cancer patients treated with external beam
radiotherapy (with/without hormonal therapy, with/without a
previous prostatectomy, no brachytherapy) and complete 2-year
follow-upwere included. Details on the REQUITE population are
given in Seibold et al. (14).
Prostate cancer patients were recruited prior to radiotherapy
between April 2014 and October 2016. Recruitment was at ten
main sites in eight countries (Belgium, France, Germany, Italy,
the Netherlands, Spain, UK, US). Conventionally fractionated
or hypo-fractionated radiotherapy was prescribed according to
local standard-of-care regimens. The patients were followed
prospectively for at least 24 months, with longer follow-
up encouraged where possible. All patients gave written
informed consent. The study was approved by local Ethical
Committees and is registered at www.controlled-trials.com
(ID ISRCTN98496463).
Demographic, co-morbidity, treatment, physics, longitudinal
toxicity (CTCAE v4.0 healthcare professional and patient
reported), quality-of-life, and treatment outcome data were
collected prospectively using standardized case report forms.
CTCAE v4.0 based questionnaires developed to collect patient
reported outcomes were adapted from those published elsewhere
for themale pelvis (19) and updated to fit with CTCAE v4.0 items.
All patients donated at least two blood samples prior to the
start of radiotherapy: an EDTA sample for SNP genotyping
plus a PAXgene sample. Genotyping data were generated using
the Illumina Infinium OncoArray-500K beadchip. Following
standard quality control procedures (20), genotype data were
imputed using the 1,000 Genomes Project (version 3) as a
reference panel.
Selection of Genetic Risk Factors
We undertook a comprehensive search of Medline and
PubMed databases using the keywords “prostate,” “prostatic,”
“radiotherapy,” “radiation,” “irradiation,” “toxicity,” “adverse
effects,” “side-effects,” “morbidity,” “injury,” “genetic variation,”
“SNP,” “GWAS,” and “polymorphism.” This search identified 60
SNPs published (up to May 31st, 2019) in GWAS patient studies
with p < 1.0·10−5 and where findings were adjusted for multiple
comparisons OR in studies including a controlled number of
SNPs (∼102) and using multivariable regularization methods
coupled to internal validation to control overfitting.
Forty-three of 60 SNPs were available for the REQUITE
population (either directly determined or after imputation) and
were included in the analysis. These SNPs were identified in five
papers (5, 11, 21–23) and the full list is reported in Table 1.
Outcome Endpoints
Toxicity endpoints were defined using CTCAE v4.0 scoring
reported by health professionals or Patient Reported Outcomes,
as detailed for each single endpoint. As the frame of the DSAE
is to identify SNPs who would tag a patient as exceptionally
“sensitive” to radiation (an “outlier”), patients with other possible
known intrinsic higher risk of exhibiting radiation toxicity
were always excluded, in particularly patients who had systemic
lupus erythematosus, rheumatoid arthritis and other collagen
vascular diseases.
The following endpoints were considered:
1. Late rectal bleeding grade≥1 (CTCAE v4.0 scoring):
patients exhibiting at least mild bleeding (even requiring no
intervention) at 12 or at 24 months. Patients with grade≥1 at
baseline and grade≤1 during follow-up were considered as
not bleeders; patients with hemorrhoids before radiotherapy
treatment were excluded.
2. Late urinary frequency grade≥2 (CTCAE v4.0 scoring):
patients with urinary frequency limiting instrumental
activities of daily living or if urinary frequency requiting
medical management at 12 or at 24 months. Patients with
urinary frequency grade≥2 at baseline and grade≤2 during
follow-up were considered as not exhibiting this endpoint.
3. Late haematuria grade ≥1 (CTCAE scoring): patients with
asymptomatic haematuria (clinical or diagnostic observations
only, no intervention indicated) at 12 or 24 months. Patients
with haematuria grade≥1 at baseline and grade≤1 during
follow-up were considered as not exhibiting the endpoint.
4. Late nocturia grade ≥2 (Patient Reported Outcome): patients
declaring need to urinate at least two-three times per night
at 12 or 24 months. Patients with nocturia grade≥2 at
baseline and grade≤2 during follow-up were considered as not
exhibiting the endpoint.
5. Late grade≥1 (Patient Reported Outcome): patients scored
with hesitant or dripping stream at 12 or 24 months. Patients
with decreased urinary stream grade≥1 at baseline and
grade≤1 during follow-up were considered as not exhibiting
the endpoint.
Patients who underwent transurethral resection of the bladder
and patients on anti-muscarinic drugs (factors which could
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TABLE 1 | Full list of SNPs selected from the literature for validation and
associated toxicity endpoint following prostate radiotherapy.
SNP OR p-value References
Rectal bleeding
rs10519410 3.7 1.3 × 10−6 (21)
rs17055178 1.95# 6.2 × 10−10 (23)
Urinary frequency
rs17599026 3.12 4.16 × 10−8 (5)
rs342442 0.51 3.86 × 10−7 (5)
rs8098701 2.41 2.11 × 10−6 (5)
rs7366282 3.2 2.03 × 10−6 (5)
rs10209697 2.66 2.27 × 10−6 (5)
rs4997823 0.49 2.35 × 10−6 (5)
rs7356945 1.74 3.71 × 10−6 (5)
rs6003982 0.51 4.28 × 10−6 (5)
rs10101158 1.8 4.39 × 10−6 (5)
Decreased urinary stream
rs7720298 2.71 3.21 × 10−8 (5)
rs17362923 2.7 6.79 × 10−7 (5)
rs76273496 3.68 2.71 × 10−6 (5)
rs144596911 3.6 2.94 × 10−6 (5)
rs62091368 4.36 3.95 × 10−6 (5)
rs141342719 3.5 3.97 × 10−6 (5)
rs673783 2.49 4.33 × 10−6 (5)
rs10969913 3.92# 2.9 × 10−10 (23)
Haematuria
rs11122573 1.92# 1.8 × 10−8 (23)
rs708498 0.24 n.a.§ (22)
rs845552 0.95 n.a.§ (22)
Nocturia
rs1799983 0.19 n.a.§ (22)
rs1045485 0.27 n.a.§ (22)
Overall toxicity (STAT# score)
rs10497203* 1.48 8.84 × 10−11 (11)
rs7582141* 1.45 4.64 × 10−11 (11)
rs6432512* 1.42 1.97 × 10−10 (11)
rs264651* 1.49 1.48 × 10−7 (11)
rs264588* 1.45 3.08 × 10−10 (11)
rs264631* 1.43 6.4 × 10−10 (11)
rs147596965 1.95 6.19 × 10−8 (5)
rs77530448 1.43 7.36 × 10−8 (5)
rs4906759 1.73 1.55 × 10−7 (5)
rs71610881 1.82 5.41 × 10−7 (5)
rs141799618 1.55 1.22 × 10−6 (5)
rs2842169 1.32 1.45 × 10−6 (5)
rs11219068 1.32 1.74 × 10−6 (5)
rs8075565 1.32 2.20 × 10−6 (5)
rs6535028 1.34 2.70 × 10−6 (5)
rs4775602 1.26 3.20 × 10−6 (5)
rs7829759 1.39 3.84 × 10−6 (5)
rs79604958 1.60 4.33 × 10−6 (5)
rs12591436 1.20 5.66 × 10−6 (5)
#overall toxicity as defined by calculating the Standardized Total Average Toxicity (STAT)
score (24).
*All these variants are highly correlated in European populations and represent the same
association signal. See also correlation matrix as determined in the REQUITE population
in the Supplementary Figure 1.
#Hazard Ratio.
§SNPs were selected using Least Absolute Shrinkage and Selection Operator (LASSO)
multivariable regression out of a panel of 384 previous identified SNPs, p-value
not available.
constitute a confounding factor in the scoring of urinary toxicity)
were excluded when considering all urinary endpoints.
Deep Sparse AutoEncoder for SNPs
Validation
The methodology described in Massi et al. (25) was considered.
This method proposes a novel feature selection algorithm for
the minority class in an imbalanced dataset, i.e., in cases like
this dataset, where there is a strong imbalance between the
number of patients that are scored as healthy (without side
effects) vs. unhealthy (with side effects). The approach uses a
representation learning technique, specifically a Deep Sparse
AutoEncoder, to obtain the best representation of the majority
class (healthy patients in this dataset) and to consequently
identify which features (SNPs) distinguish the minority class
(unhealthy patients) with respect to the majority class.
An AutoEncoder (AE) is a neural network with an output
that reconstructs the input (26). In its simplest version an AE
is composed of the input, the output and only a single hidden
layer. The input layer in our case is composed of J nodes, one
per feature (one per SNP), and we consider a data matrix X, in
which each row xi is the vector of SNPs recorded for the patient
i, i ∈ {1 ,.., N}. The input layer is connected to the hidden layer,
hi, through the encoder function, f, such that hi = f (Wxi +b);
here W ∈ R H×J denotes the weight matrix and b ∈ RH×1 the
bias vector. Then, the output is the result of the application of a
decoder function, g, to the hidden layer hi, such that x̂i = g (W’hi
+b’), where W’ ∈ R J×H is the weight matrix and b ∈ R J×1 is
the bias vector. Having fixed the functions f and g, the training
of the network consists in estimating the corresponding optimal
parameters (W, b, W’, b’), by minimizing the loss function L(xi,
x̂i), which is a function that gives a measure of the similarity
between the input and the reconstructed output. In this work, we
considered the Euclidean distance as loss function L.
A more sophisticated version of AE (named Deep AE) has
multiple hidden layers in which the output of a layer is the
input of the next one. Figure 1 depicts a simplified scheme of a
Deep AutoEncoder.
In order to get an effective reconstruction of the input, that
allows selection of features that best characterize the input
data, we included a penalization term in the loss function. AE
algorithms of this type are known as Deep Sparse AEs. Given this
framework and with the final goal of validating the SNPs effect
on the long-term radiation toxicity, we applied the previously
described Deep Sparse AE as follows:
(i) sampling: we sampled S healthy patients (those without
toxicity) where S equals the total number of unhealthy patients
(those with toxicity). All the unhealthy patients and the S
sampled healthy patients form the test set. All the remaining
healthy patients constitute the training set.
(ii) training: we trained the network only on the previously
specified training set. The idea here was to learn how to best
represent healthy patients. The result of this step is the estimate
of the neural network characteristics (weight and bias vectors,
encoder and decoder functions).
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FIGURE 1 | Simplified scheme of a Deep AutoEncoder.
FIGURE 2 | Schematic representation of the workflow used to identify which features to select to characterize the minority class (i.e., patients with toxicity) with
respect to the majority class (patients without toxicity).
(iii) testing: we tested the estimated network on the previously
specified test set. The result of this step is a matrix of
Reconstruction Errors, R ∈ R(2S)×J. Considering the previous
step and the fact that unhealthy patients are the minority
class, the rows of R which are related to unhealthy patients
should contain higher values with respect to those rows of R
associated to healthy patients.
(iv) SNP identification: we identified which SNPs are associated
with the highest Reconstruction Error. Further details on this
step are given at the end of this section.
The steps (i)-(iii) are repeated 50 times in order to reduce a
possible selection bias induced by the sampling step (i), thus
obtaining 50 Rmatrices.
In order to identify which features should be selected
for characterizing the minority class with respect to the
majority class, in step (iv) the average Reconstruction Error
per feature per class is computed according to that proposed
in Massi et al. (25), which means computing two vectors
(one for the unhealthy patients and one for the healthy
patients), both made by J elements. Then, we investigated
the distribution of the difference, 1, between the average
Reconstruction Errors related to unhealthy patients and the
average Reconstruction Errors related to healthy patients.
See Figure 2 for a schematic representation of the above
described workflow.
Finally, to define which SNPs are associated with late toxicity
endpoints, we set possible thresholds equal to the 70-th, 80-
th, the 90-th and the 95-th percentiles of the distribution of
the Reconstruction Error differences, 1. This means that we
investigated the SNPs associated with the top 30%, the top
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20%, the top 10% and the top 5% differences. These thresholds
identity the effect size of identified SNPs, a large effect size (Odds
Ratio>2) for SNPs in the 90-th/95-th percentiles, a moderate
(Odds Ratio∼2) and small (Odds Ratio<2) effect size for SNPs
in the 80-th and 70-th percentiles, respectively.
Architectural and Implementation Details
For the interested reader, in this section we provide some
more specific details regarding the development and specific
implementation of the DSAE for the applications described in
this paper. For more details on the methodology, its strenghts
FIGURE 3 | Results for late rectal bleeding grade≥1 from the Deep Sparse AutoEncoder. The 43 considered SNPs are reported in the x-axis and the averaged
Reconstruction Errors (RE) are reported in the y-axis (top panel), red columns refer to patients with toxicity, while blue columns refer to patients without toxicity. In the
lower panel the difference between averaged Reconstruction Errors between the two classes are represented for each SNP (i.e., differences between red and blue
columns). For most SNPs, the difference is close to zero (red line in the bottom panel of the figure). The chosen thresholds in this difference (i.e., highest 30, 20, 10,
and 5% differences) are selecting SNPs associated to the toxicity outcome. Green circles refer to SNPs that were previously identified as associated with late rectal
bleeding, while blue circles refer to SNPs that were previously associated with overall toxicity as defined by calculation of the Standardized Total Average Toxicity
(STAT) score (24). Red stars indicate SNPs (either specific for this endpoint or related to overall toxicity) defining patients with toxicity as outliers with respect to the
characteristics of patients without toxicity. Labels show SNPs that not directly associated with late rectal bleeding/overall toxicity, but contributing to their identification.
The label states for which toxicity endpoint the SNPs were originally associated with in the literature: FREQ=urinary frequency, HEMA=haematuria, NOCT=nocturia,
STREAM=decreased urinary stream.
TABLE 2 | Deep Sparse AutoEncoder testing of SNPs associated with Late Rectal Bleeding*.












SNPs previously associated with late rectal bleeding
rs10519410 (21) Not validated Not validated Not validated Not validated
rs17055178 (23) Not validated Not validated Not validated Not validated
SNPs previously associated with overall toxicity (STAT score)
rs264631 (11) Identified Identified Not validated Not validated
rs141799618 (5) Identified Identified Not validated Not validated
*grade≥1 (all considered SNPs reported in the table) and to overall toxicity as defined by calculation of the Standardized Total Average Toxicity (STAT) score (24) (in this case only
“Identified” SNPs were reported in the table). The SNPs that were correctly identified by the algorithm are flagged as “Identified”.
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and all model’s hyperparameters mentioned below, refer to the
description in Massi et al. (25).
The experiments were implemented and carried out using
Python Keras framework for Deep Learning with Tensorflow
as backend.
For better comparability of results in the experiments we
structured the DSAEs included in the sampling-training-testing
procedure with the same architecture and hyperparameters for
all five endpoints. In particular, all the encoders of the DSAEs
were composed of an input layer with J = 43 nodes (one
per SNP), followed by a sequence of hidden layers of 40, 30
(with hyperbolic tangent activation function) and 20 nodes,
respectively. To the 20 nodes of the innermost hidden layer we
applied a sigmoidal activation function to foster the sparsity
induced by the penalization term (weighted with λ =10e-5). The
decoder architecture of all DSAEs was specular to the encoder,
with a sequence of layers with 30 and 40 nodes, followed by an
output layer of J = 43 nodes. The training of the DSAE for each
of the B= 50 iterations was performed for 400 epochs, exploiting
the Adam optimization algorithm with its default parameters
(learning rate equal to 0.001).
RESULTS
Cohort
REQUITE enrolled 1,681 prostate cancer patients who were
treated with external beam radiotherapy without brachytherapy.
One thousand four hundred and fifty patients with complete 2-
year follow-up were available for analysis. Forty-nine patients
were excluded because of an intrinsic higher risk of exhibiting
radiation toxicity, due to their co-morbidities (patients with a
diagnosis of systemic lupus erythematosus, rheumatoid arthritis
and other collagen vascular diseases). Details on the clinical
characteristics of the cohorts selected for each toxicity endpoint
are given in Supplementary Tables 1,2.
Validation of SNPs Associated With Late
Toxicity Endpoints Through a Deep Sparse
AutoEncoder
Late Rectal Bleeding grade≥1
One hundred and sixty of 1,366 available patients (11.7%) had
late rectal bleeding grade≥1. Figure 3 shows the differences
between averaged Reconstruction Errors between the two classes
FIGURE 4 | Results for late urinary frequency grade≥2 from the Deep Sparse AutoEncoder. The 43 considered SNPs are reported in the x-axis and the averaged
Reconstruction Errors (RE) are reported in the y-axis (top panel), red columns refer to patients with toxicity, while blue columns refer to patients without toxicity. In the
lower panel the difference between averaged Reconstruction Errors between the two classes are represented for each SNP (i.e., differences between red and blue
columns). For most SNPs, the difference is close to zero (red line in the bottom panel of the figure). The chosen thresholds in this difference (i.e., highest 30, 20, 10,
and 5% differences) are selecting SNPs associated to the toxicity outcome. Green circles refer to SNPs that were previously identified as associated with late urinary
frequency, while blue circles refer to SNPs that were previously associated with overall toxicity as defined by calculation of the Standardized Total Average Toxicity
(STAT) score (24). Red stars indicate SNPs (either specific for this endpoint or related to overall toxicity) defining patients with toxicity as outliers with respect to the
characteristics of patients without toxicity. Labels show SNPs that not directly associated with late urinary frequency/overall toxicity, but contributing to their
identification. The label states for which toxicity endpoint the SNPs were originally associated with in the literature: BLEE=rectal bleeding, HEMA=haematuria,
NOCT=nocturia, STREAM=decreased urinary stream.
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(i.e., differences between red and blue columns). The largest part
of the differences is close to zero (red line in the bottom panel of
Figure 3). The chosen thresholds in this difference (i.e., highest
30, 20, 10, and 5% differences) select SNPs associated with the
toxicity outcome with different effect size. Table 2 lists results
for the SNPs previously reported to be associated with late rectal
bleeding and overall toxicity in comparison with SNPs selected by
the DSAE in the REQUITE cohort. For late rectal bleeding eight
SNPs were identified, two SNPs previously associated with overall
toxicity (red stars in Figure 3) and six SNPs previously found to
be associated with urinary toxicity.
Late Urinary Frequency Grade≥2
Fifty-six of 1,334 available patients (4.2%) experienced late
urinary frequency grade≥2. Patients were excluded from the
analysis if they had urinary frequency grade≥2 at baseline
(n= 26), they underwent transurethral resection of the bladder
(n= 31) or were using anti-muscarinic drugs (n= 10). Figure 4
and Table 3 show that the DSAE analysis identified 14 SNPs:
four already reported as associated with urinary frequency
(rs17599026, rs8098701, rs7366282, rs10209697), four associated
with overall toxicity, one previously associated with bleeding and
five with other urinary symptoms.
Late Haematuria Grade≥1
Seventy-four of 1,343 available patients (5.5%) experienced late
haematuria grade≥1. Seventeen patients were excluded from the
analysis because they had haematuria at baseline grade≥1, while
41 were excluded because underwent transurethral resection
of the bladder or were using anti-muscarinic drugs. Figure 5
and Table 4 report DSAE results for this endpoint: 10 SNPs
were identified. Two SNPs already associated with haematuria
(rs708498 and rs845552), five SNPs associated with overall
toxicity, and three SNPs with other urinary symptoms.
Late Nocturia Grade≥2
Two hundred and twenty-three patients out of 1,250 available
patients (17.8%) experienced late nocturia grade≥2. One
hundred and ten patients were excluded from analysis because
they had nocturia grade≥2 at baseline, while 41 were excluded
because underwent transurethral resection of the bladder
or were using anti-muscarinic drugs. Figure 6 and Table 5
report results for the validation through DSAE in the
REQUITE population. Eleven SNPs were identified: one SNP
already found to be associated with nocturia, four with
overall toxicity, one with bleeding and five with other
urinary symptoms.
Late Decreased Urinary Stream Grade≥1
Two hundred and eleven out of 1,234 available patients (17.1%)
experienced late decreased stream grade≥1. One hundred and
twenty-six patients were excluded from analysis because they
had decreased stream grade≥1 at baseline, while 41 were
excluded because underwent transurethral resection of the
bladder or were using anti-muscarinic drugs. Eleven SNPs were
selected: two SNPs previously identified for decreased urinary
stream (rs76273496 and rs673783), two for overall toxicity, six
for other urinary symptoms and one for bleeding (Figure 7
and Table 6).
Classical Validation Approach Using
Univariate Analysis
A simple validation approach, using univariate logistic analysis,
identified eight SNPs with p < 0.05 (range 0.01–0.05), none of
them is validated when considering the Bonferroni correction for
multiple testing, which would require p < 0.0011 in this case.
Detailed results are presented in Supplementary Table 4.
TABLE 3 | Results from Deep Sparse AutoEncoder testing of SNPs associated with Urinary Frequency*.












SNPs previously associated with late urinary frequency
rs17599026 (5) Identified Identified Identified Not validated
rs342442 (5) Not validated Not validated Not validated Not validated
rs8098701 (5) Identified Identified Identified Identified
rs7366282 (5) Identified Identified Identified Identified
rs10209697 (5) Identified Identified Not validated Not validated
rs4997823 (5) Not validated Not validated Not validated Not validated
rs7356945 (5) Not validated Not validated Not validated Not validated
rs6003982 (5) Not validated Not validated Not validated Not validated
rs10101158 (5) Not validated Not validated Not validated Not validated
SNPs previously associated with overall toxicity (STAT score)
rs147596965 (5) Identified Not validated Not validated Not validated
rs77530448 (5) Identified Identified Identified Identified
rs8075565 (5) Identified Not validated Not validated Not validated
rs12591436 (5) Identified Not validated Not validated Not validated
*Late Urinary Frequency grade≥2 (all considered SNPs reported in the table) and to overall toxicity as defined by calculation of the Standardized Total Average Toxicity (STAT) score (24)
(in this case only “Identified” SNPs were reported in the table). The SNPs that were correctly identified by the algorithm are flagged as “Identified.”
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FIGURE 5 | Results for late haematuria grade≥1 from the Deep Sparse AutoEncoder. The 43 considered SNPs are reported in the x-axis and the averaged
Reconstruction Errors (RE) are reported in the y-axis (top panel), red columns refer to patients with toxicity, while blue columns refer to patients without toxicity. In the
lower panel the difference between averaged Reconstruction Errors between the two classes are represented for each SNP (i.e., differences between red and blue
columns). For most SNPs, the difference is close to zero (red line in the bottom panel of the figure). The chosen thresholds in this difference (i.e., highest 30, 20, 10,
and 5% differences) are selecting SNPs associated to the toxicity outcome. Green circles refer to SNPs that were previously identified as associated with late
haematuria, while blue circles refer to SNPs that were previously associated with overall toxicity as defined by calculation of the Standardized Total Average Toxicity
(STAT) score (24). Red stars indicate SNPs (either specific for this endpoint or related to overall toxicity) defining patients with toxicity as outliers with respect to the
characteristics of patients without toxicity. Labels show SNPs that not directly associated with late haematuria/overall toxicity, but contributing to their identification.
The label states for which toxicity endpoint the SNPs were originally associated with in the literature: BLEE=rectal bleeding, FREQ=urinary frequency,
NOCT=nocturia, STREAM=decreased urinary stream.
TABLE 4 | Results from Deep Sparse AutoEncoder testing of SNPs associated with Late Haematuria*.












SNPs previously identified as associated to late haematuria
rs11122573 (23) Not validated Not validated Not validated Not validated
rs708498 (22) Identified Identified Identified Not validated
rs845552 (22) Identified Identified Not validated Not validated
SNPs previously identified as associated to overall toxicity (STAT score)
rs147596965 (5) Identified Identified Identified Not validated
rs77530448 (5) Identified Identified Not validated Not validated
rs7829759 (5) Identified Identified Not validated Not validated
rs79604958 (5) Identified Identified Not validated Not validated
rs12591436 (5) Identified Identified Not validated Not validated
*Late Haematuria grade≥1 (all considered SNPs reported in the table) and to overall toxicity as defined by calculation of the Standardized Total Average Toxicity (STAT) score (24) (in
this case only “Identified” SNPs were reported in the table). The SNPs that were correctly identified by the algorithm are flagged as “Identified”.
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FIGURE 6 | Results for late nocturia grade≥2 from the Deep Sparse AutoEncoder. The 43 considered SNPs are reported in the x-axis and the averaged
Reconstruction Errors (RE) are reported in the y-axis (top panel), red columns refer to patients with toxicity, while blue columns refer to patients without toxicity. In the
lower panel the difference between averaged Reconstruction Errors between the two classes are represented for each SNP (i.e., differences between red and blue
columns). For most SNPs, the difference is close to zero (red line in the bottom panel of the figure). The chosen thresholds in this difference (i.e., highest 30, 20, 10,
and 5% differences) are selecting SNPs associated to the toxicity outcome. Green circles refer to SNPs that were previously identified as associated with late nocturia,
while blue circles refer to SNPs that were previously associated with overall toxicity as defined by calculation of the Standardized Total Average Toxicity (STAT) score
(24). Red stars indicate SNPs (either specific for this endpoint or related to overall toxicity) defining patients with toxicity as outliers with respect to the characteristics of
patients without toxicity. Labels show SNPs that not directly associated with late nocturia/overall toxicity, but contributing to their identification. The label states for
which toxicity endpoint the SNPs were originally associated with in the literature: BLEE=rectal bleeding, FREQ=urinary frequency, HEMA=haematuria,
STREAM=decreased urinary stream.
TABLE 5 | Results from Deep Sparse AutoEncoder testing of SNPs associated with Late Nocturia*.












SNPs previously identified as associated to late nocturia
rs1799983 (22) Identified Not validated Not validated Not validated
rs1045485 (22) Not validated Not validated Not validated Not validated
SNPs previously identified as associated to overall toxicity (STAT score)
rs10497203 (11) Identified Identified Not validated Not validated
rs264651 (11) Identified Identified Not validated Not validated
rs77530448 (5) Identified Identified Not validated Not validated
rs11219068 (5) Identified Identified Not validated Not validated
*Late Nocturia grade≥2 (all considered SNPs reported in the table) and to overall toxicity as defined by calculation of the Standardized Total Average Toxicity (STAT) score (24) (in this
case only “Identified” SNPs were reported in the table). The SNPs that were correctly identified by the algorithm are flagged as “Identified”.
DISCUSSION
In recent years Normal Tissue Complication Probability (NTCP)
models have been developed to attempt to predict before the
start of treatment patients at risk of long-term radiation toxicity.
These recent developments were also characterized by the shift
from NTCP dose-based modeling to the wider field of more
“comprehensive” predictive models. In the speculative case that
two patients receive exactly the “same dose distribution,” the risk
of toxicity is always modulated by the single individual profile.
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FIGURE 7 | Results for late decreased urinary stream grade≥1 from the Deep Sparse AutoEncoder. The 43 considered SNPs are reported in the x-axis and the
averaged Reconstruction Errors (RE) are reported in the y-axis (top panel), red columns refer to patients with toxicity, while blue columns refer to patients without
toxicity. In the lower panel the difference between averaged Reconstruction Errors between the two classes are represented for each SNP (i.e., differences between
red and blue columns). For most SNPs, the difference is close to zero (red line in the bottom panel of the figure). The chosen thresholds in this difference (i.e., highest
30, 20, 10, and 5% differences) are selecting SNPs associated to the toxicity outcome. Green circles refer to SNPs that were previously identified as associated with
late decreased urinary stream, while blue circles refer to SNPs that were previously associated with overall toxicity as defined by calculation of the Standardized Total
Average Toxicity (STAT) score (24). Red stars indicate SNPs (either specific for this endpoint or related to overall toxicity) defining patients with toxicity as outliers with
respect to the characteristics of patients without toxicity. Labels show SNPs that not directly associated with late decreased urinary stream /overall toxicity, but
contributing to their identification. The label states for which toxicity endpoint the SNPs were originally associated with in the literature: BLEE=rectal bleeding
FREQ=urinary frequency, HEMA=haematuria, NOCT=nocturia.
The fact that “dose is not enough” was clear from the early
days of radiobiology but is receiving constantly growing attention
in the current “omics” epoch (Bentzen, 2006): the availability
of individual information characterizing patients and potentially
influencing their reactions to radiation is increasingly important,
especially in the era of image-guided radiotherapy that can spare
the organs at risk in most patients.
The purpose of any predictive model in oncology is to
provide valid outcome predictions for new patients. Essentially,
the main interest of a dataset used to develop a model
is to learn for the future. Systematic validation in multi-
center collaborative settings hence is a crucial aspect in the
process of predictive modeling. REQUITE is the largest multi-
center observational study in this field to date, collecting
standardized data longitudinally. The study was specifically
designed to enable validation of models and biomarkers that
predict a patient’s risk of developing long-term side-effects
following radiotherapy.
The present work focused on the validation of findings from
previous GWAS of radiation toxicity after radiotherapy for
prostate cancer. To the best of our knowledge, few validation
studies in this frame have been conducted so far. Barnett et al.
(13) performed an independent validation study of 92 SNPs in
46 genes in a large cohort of breast (976 patients) and prostate
(637 patients) cancer patients who received radiotherapy. They
focused on five rectal (bleeding, proctitis, sphincter control, stool
frequency, tenesmus) and four urinary endpoints (frequency,
nocturia, incontinence, and decreased stream) reported by
patients 2 years after radiotherapy. An additional endpoint
of overall toxicity as measured by the STAT score was also
considered. None of the investigated associations was confirmed
after adjustment for multiple comparisons.
Genome-wide radiogenomic studies are identifying and
validating SNPs. However, to date these studies have relied on the
classical single marker association test (both in the discovery and
validation setting), which is hampered by the need for multiple-
testing corrections. For typical study sizes, this method can detect
only relatively large effect size and has limited power to identify
reliably modest effects from the many SNPs that are likely to
contribute to a polygenic risk profile associated with radiation
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TABLE 6 | Results from Deep Sparse AutoEncoder testing of SNPs associated with Late Decreased Urinary Stream*.












SNPs previously identified as associated to late decreased urinary stream
rs7720298 (5) Not validated Not validated Not validated Not validated
rs17362923 (5) Not validated Not validated Not validated Not validated
rs76273496 (5) Identified Identified Identified Not validated
rs144596911 (5) Not validated Not validated Not validated Not validated
rs62091368 (5) Not validated Not validated Not validated Not validated
rs141342719 (5) Not validated Not validated Not validated Not validated
rs673783 (5) Identified Not validated Not validated Not validated
rs10969913 (23) Not validated Not validated Not validated Not validated
SNPs previously identified as associated to overall toxicity (STAT score)
rs77530448 (5) Identified Not validated Not validated Not validated
rs6535028 (5) Identified Not validated Not validated Not validated
*Late Decreased Urinary Stream grade≥1 (all considered SNPs reported in the table) and to overall toxicity as defined by calculation of the Standardized Total Average Toxicity (STAT)
score (24) (in this case only “Identified” SNPs were reported in the table). The SNPs that were correctly identified by the algorithm are flagged as “Identified”.
toxicity. Genome-wide studies miss SNPs that make small but
real contributions to risk.
Machine learning has already been proposed as a promising
alternative approach to estimate overall genetic risk (27). The
approach can identify multiple SNPs with small effects that
together but not individually reach genome-wide significance.
Two studies have already proposed machine learning methods to
identify SNP-based signatures associated with late toxicity after
radiotherapy for prostate cancer (27, 28).
Here, we extended the use of machine learning methods
by using a method that addresses an important limitation of
studies on radiation toxicity: the imbalance of classes, with
a lower frequency of patients with vs. without late toxicity.
This imbalance is important because it can lead to sub-optimal
solutions (29), even when datasets are used for validation.
As a first step in testing our approach, we attempted to and
were successful in validating previously reported associations
identified in studies based on classical single marker association
tests. The next step will be a de novo analysis to identify SNPs with
smaller individual effects.
Dealing with imbalance requires non-classical statistical
solutions. Here, we explore novel methods for feature selection
that come from the Deep Learning research field (25). Indeed,
deep learning approaches, with their intrinsic hierarchical
structure (where each layer realizing a combination of the
previous layer), seem particularly adept at mimicking complex
dependencies within data. Deep learning has already been
applied and shown to have potential in similar bioinformatics
research areas, such as for modeling the competition between
splice sites (30) and in predicting RNA- and DNA-binding
specificity (31).
We used DSAE to obtain the best possible representation
of the majority class (without toxicity) and so to identify
which features (SNPs) distinguish the minority class (with
toxicity). The encoder and decoder functions are usually non-
linear (i.e., sigmoid, hyperbolic tangent, rectified linear unit
etc.), which enables a better reconstruction of the input by
the capture of complex non-linear relationships among SNPs.
Training on healthy patients allows the overall SNP pattern
of normal radio-sensitivity to be established. Testing measures
the “distance” between each new patient and the pattern of
normal radio-sensitivity to identify SNPs associated with the
highest reconstruction errors (i.e., highest distances) between
the pattern of normality and the SNP profile of patients scored
with toxicity (i.e., radio-sensitive patients). The distribution of
the reconstructed errors allows identification and classification
of SNPs with very large/large effect (SNPs associated with the
top 95th percentile and 90th percentile of the distribution of
reconstructed errors) and with moderate/small effects (SNPs
associated with the top 80th percentile and 70th percentile of the
distribution of reconstructed errors).
The DSAE successfully validated multiple SNPs contributing
to an increased risk of toxicity. Some SNPs were already
associated with the specific considered endpoint, others were
previously associated with overall toxicity, and some were
previously associated with other toxicities.
As common in GWAS, many significant SNPs lie in
non-coding regions, and it is premature to speculate on
their functional significance. We refer readers to the original
publications which discuss possible gene functions (5, 11, 23),
but give an example to illustrate likely clinical relevance. DSAE
validated two SNPs previously associated with haematuria,
rs708498 and rs845552, which are located in the PTGER2
and EGFR genes, respectively. PTGER2 (widely distributed
in humans) encodes Prostaglandin E2 receptor 2. Irradiation
causes hypermethylation of this antifibrotic gene (32). EGFR
has been shown to play a critical role in TGF-β1 dependent
fibroblast to myofibroblast differentiation (33). These two SNPs
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were also identified for urinary stream (rs845552) and urinary
frequency (rs708498).
The main strength of our study is use of a large international
prospective multi-center cohort of patients treated with modern
radiotherapy techniques and fractionation schemes. The patients
were specifically enrolled to validate models and biomarkers
for predicting radiation toxicity, and the study design involved
a standardized data collection scheme for collecting healthcare
professional and patient-reported outcomes. The extensive role
of data management also allowed for quality assurance of data
collected, and we used “real world” data coming from “data-
farming” (34).
A possible limitation of our study was use of 2-year follow-up
toxicity data. The REQUITE study is still maturing, normal tissue
reactions in the intestinal and urinary tract develop gradually
from 6 months after radiotherapy till to around 3 years for the
intestinal syndrome and to 5 years for the urinary syndrome.
Recent additional funding is allowing extension of the REQUITE
study with the aim of reaching standardized collection of follow-
up data till year 5.
The use of grade 1 and grade 2 events is another possible
limitation of this study. As the application of deep learning
techniques requires a suitable number of events, the choice
of mild or moderate (when possible) toxicity was forced by
the number of morbidity events registered in the REQUITE
population. The low number of severe toxicity is for sure a
reflection of modern radiotherapy techniques which allow a
substantial sparing of normal tissues, at least for the case of
prostate cancer irradiation. Yet, some grade 1 and grade 2
toxicity can assume a chronic behavior, with substantial impact
on the quality of life of long term survivors, for example,
this could happen, for grade 2 urinary frequency and nocturia
which are impairing daily activities and the quality of sleep
for many years (35). A further point, more associated to
research rather to clinical activity, is related to the possibility
that the same genes/variants predispose to severe toxicity that
predispose to low-grade toxicity. A realistic hypothesis is that
some genes/variants will be common and others will be unique
to severe toxicities. For example, ATM seems to be important
for both mild and severe toxicity, though the particular variants
differ with common SNPs associated with any toxicity, but rare
mutations associated with severe toxicity. We think we can make
a good case that genes identified via GWAS of mild toxicity
represent good candidates for subsequent sequencing studies
to identify rare mutations that may be associated with severe
toxicities. Probably there are at least some biologic mechanisms
common to both mild and severe toxicity, though the optimal
genomic signature for each may differ. Our work still adds
value by pointing to the candidate genes or loci that are likely
important for both.
We have shown our approach is worth studying further and
the next step would be to use it to identify patterns of SNPs to
define polygenic risk scores that can be included into integrated
normal tissue complication probability models, together with
validated dosimetric and clinical risk factors.
The DSAE methodology underlines that, within the current
RT, experiencing no toxicity could be considered as the
“normal” situation, with patients with mild/moderate toxicity
being outliers. The possible knowledge of the single patient
intrinsic radiosensitivity and the identification of these outlier
subjects could help in tailoring decision making. This should
not entail changing the probability of tumor control to
avoid mild/moderate side-effects, yet it should be focused on
maximizing uncomplicated tumor control, even considering
the patient inclination toward the different side-effects. The
availability of such models would be relevant for the clinic,
allowing the single patient optimization, thus constituting
an important step toward the implementation of predictive
modeling in the clinic. This approach would allow tailoring of
therapeutic approach (i.e., active surveillance vs. prostatectomy
vs. brachytherapy vs. external beam radiotherapy) and of doses
(both to tumor and organs at risk) to the specific patient
anatomy, clinical situation and individual biology. Combining
biological stratification with toxicity reducing techniques (such
as imaging fusion, image guidance, fractionation and reduced
margins for Planning Target Volume) could further decrease
treatment related toxicity rates and allow for dose escalation to
enhance tumor control. Integrated predictive models will also be
an essential tool in the design of interventional trials to modify
the radiotherapy strategies. A detailed discussion of the potential
ways in which biomarker/SNP assays might be implemented in
routine clinical practice can be found in Azria et al. (7).
Other future work could study the possibility of “scaling” the
use of DSEAs to the discovery of new genetic signatures using the
whole GWAS information available in the REQUITE population,
thus achieving the possibility of considering millions of features
to detect outliers.
CONCLUSION
A deep learning approach can validate SNPs associated with
toxicity after radiotherapy. The method can identify complex
SNP signatures for multiple toxicity endpoints and should be
studied further to extract polygenic risk scores to include in
integrated normal tissue complication probability models that
could be used to personalize radiotherapy planning.
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